Candidates of Genomic Tests in HR+/HER2- Breast Cancer Patients With 1-2 Positive Sentinel Lymph Node Without Axillary Lymph Node Dissection: Analysis From Multicentric Cohorts

BACKGROUND: The genomic tests such as the MammaPrint and Oncotype DX test are being gradually applied for hormone receptor positive/HER-2 negative (HR+/HER2-) breast cancer patients with up to three positive axillary lymph nodes (ALNs). The first results from RxPONDER trial suggested that Oncotype D...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Zhao, Chen, Jia-Jian, Liu, Peng-Chen, Chen, Peng, Wang, Wei-Li, Liu, Yan-Bing, Wang, Chun-Jian, Qiu, Peng-Fei, Lv, Qing, Wu, Jiong, Wang, Yong-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375498/
https://www.ncbi.nlm.nih.gov/pubmed/34422668
http://dx.doi.org/10.3389/fonc.2021.722325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375498/
https://www.ncbi.nlm.nih.gov/pubmed/34422668
http://dx.doi.org/10.3389/fonc.2021.722325

Ejemplares similares